Travere Therapeutics, Inc. (TVTX)
| Market Cap | 4.26B +189.0% |
| Revenue (ttm) | 536.20M +96.0% |
| Net Income | -21.42M |
| EPS | -0.24 |
| Shares Out | 92.99M |
| PE Ratio | n/a |
| Forward PE | 18.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,892,431 |
| Open | 46.50 |
| Previous Close | 46.18 |
| Day's Range | 45.30 - 47.77 |
| 52-Week Range | 13.88 - 48.61 |
| Beta | 1.14 |
| Analysts | Strong Buy |
| Price Target | 55.07 (+20.21%) |
| Earnings Date | May 4, 2026 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin... [Read more]
Financial Performance
In 2025, Travere Therapeutics's revenue was $490.73 million, an increase of 110.45% compared to the previous year's $233.18 million. Losses were -$25.55 million, -92.06% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $55.07, which is an increase of 20.21% from the latest price.
News
Travere Therapeutics says Filspari generally well tolerated in Phase 3 study
Travere Therapeutics (TVTX) announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension of FILSPARI in the treatment of focal segmental glomerulosclerosis. Patients who init...
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparse...
Travere Therapeutics price target raised to $62 from $59 at Citi
Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $62 from $59 and keeps a Buy rating on the shares. The company’s licensing agreement with Everest Medicines for…
Travere Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is expanding its rare disease portfolio with the acquisition of civorebrutinib and strong performance of FILSPARI in IgA nephropathy and FSGS. Clinical programs, including pegtibatinase for HCU, are progressing, and a new patent could extend exclusivity to 2037. Financial outlook remains robust, with $3 billion peak sales guidance and no near-term capital needs.
Travere Therapeutics price target raised to $67 from $57 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Travere Therapeutics (TVTX) to $67 from $57 and keeps a Buy rating on the shares after the company announced the expansion of…
Travere Therapeutics Transcript: Investor update
Announced a strategic licensing deal for civorebrutinib, a reversible BTK inhibitor with proof of concept in PMN and potential in multiple rare kidney diseases. Early clinical data show rapid, sustained efficacy and favorable safety, with plans for global development and portfolio integration.
Travere Therapeutics Press release: Investor update
Travere Therapeutics issued a press release on June 2, 2026, disclosing material business information to investors.
Travere Therapeutics Slides: Investor update
Travere Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion
Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest Medicines to develop and commercialize an experimental kidney disease drug in a deal worth up ...
Travere Therapeutics enters into exclusive licensing agreement with Everest
Travere Therapeutics (TVTX) entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib, a covalent reversible Br...
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for ...
Ligand price target raised to $266 from $263 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $266 from $263 and keeps a Buy rating on the shares after Travere Therapeutics (TVTX) announced a…
Travere Therapeutics price target raised to $59 from $50 at BofA
BofA raised the firm’s price target on Travere Therapeutics (TVTX) to $59 from $50 and keeps a Buy rating on the shares after the company announced a USPTO Notice of…
Travere confirms Notice of Allowance from USPTO for Filspari patent application
Travere Therapeutics (TVTX) last night announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamid...
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Applicatio...
Wells says new Filspari patent allowance improves Travere’s settlement leverage
Wells Fargo notes that this morning, the U.S. Patent Office published a Notice of Allowance on its intention to allow a new patent for Filspari on Travere Therapeutics (TVTX)’ IgAN…
Travere Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
FILSPARI's recent FDA approval for FSGS has been met with strong physician and patient enthusiasm, with expectations for rapid uptake and market expansion. The company is also advancing a phase III program in homocystinuria and projects significant growth opportunities in rare kidney and metabolic diseases.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants coveri...
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2026 Heal...
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior ...
Travere Therapeutics announces $400M convertible senior notes offering
Travere Therapeutics (TVTX) announced its intention to offer, subject to market and other conditions, $400M aggregate principal amount of convertible senior notes due 2032 in an underwritten offering....
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convert...
Travere Therapeutics price target raised to $60 from $45 at TD Cowen
TD Cowen raised the firm’s price target on Travere Therapeutics (TVTX) to $60 from $45 and keeps a Buy rating on the shares. The firm said Travere delivered a solid…
Travere Therapeutics price target raised to $55 from $53 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Travere Therapeutics (TVTX) to $55 from $53 and keeps an Outperform rating on the shares. Despite the Q1 Filspari miss,…
Travere Therapeutics price target raised to $59 from $53 at Citi
Citi raised the firm’s price target on Travere Therapeutics (TVTX) to $59 from $53 and keeps a Buy rating on the shares.